Moreover, with the gene expression profile from an anti-PD-L1 treatment ccRCC cohort (24), we found that these patients who responded to the immunotherapy contained a lower level of SNRPA1 (Figure 5E). Here, SNRPA1 is linked to nonpapillary renal cell carcinoma.